Back to home
CLINICAL SIGNALApril 14, 2026·6 min read
Relay's RLY-2608 Posts 11.1-Month PFS in Phase 2
The AI-designed PI3Kα inhibitor shows durable responses in HR+/HER2- breast cancer with mutant-selective specificity. A landmark for computationally designed oncology drugs.
The full analysis is published in the weekly biotech.today newsletter — subscribe for free to get the next issue in your inbox.